Please assess the completion status of the following clinical trial:

Trial Title: CardioMEMS HF System Post Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NYHA class III heart failure~* At least 1 heart failure hospitalization within previous 12 months~* Patients with reduced LVEF heart failure should be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the patient is intolerant to beta blockers, ACE-I or ARB~* BMI ≤ 35. Patients with BMI \>35 will require their chest circumference to be measured at the axillary level. If \> 65 inches the patient will not be eligible for the study.~* Pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the right heart catheterization)~Exclusion Criteria:~* Active infection~* History of recurrent (\> 1) pulmonary embolism or deep vein thrombosis~* Inability to tolerate a right heart catheterization~* A major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within previous 2 months~* Cardiac resynchronization device (CRT) implanted within previous 3 months~* Glomerular Filtration Rate (GFR) \< 25 ml/min (obtained within 2 weeks of implant) who are non-responsive to diuretic therapy or who are on chronic renal dialysis~* Congenital heart disease or mechanical right heart valve~* Likely to undergo heart transplantation or VAD within the next 6 months~* Known coagulation disorders~* Hypersensitivity or allergy to aspirin, and/or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CardioMEMS HF System Group (Type: None): Patients implanted with a CardioMEMS HF System.

Based on this trial design, predict the completion outcome and termination type (if applicable).